Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CardieX ( (AU:CQT) ) has issued an announcement.
CONNEQT Health has secured a Phase 2b clinical trial contract with a U.S.-based biopharmaceutical company to support the development of treatments for hypertension and cardiovascular disease. The trial, valued at approximately A$1.1 million, will utilize CONNEQT’s vascular assessment and monitoring platforms across 30 sites in the U.S., showcasing the company’s technology and strengthening its pharmaceutical partnerships.
More about CardieX
CONNEQT Health is a company focused on advancing medical technology in vascular health. Their product suite includes medical and home health devices, as well as digital solutions for hypertension, cardiovascular disease, and other vascular health disorders, all based on their SphygmoCor® vascular biomarker technology. The company is listed on the Australian Stock Exchange under the symbol ASX: CQT.
Average Trading Volume: 540,713
Technical Sentiment Signal: Sell
Current Market Cap: A$19.39M
For detailed information about CQT stock, go to TipRanks’ Stock Analysis page.